Targeted Prodrug Design for the Treatment of Malignant Melanoma
Journal Title: Journal of Dermatology Research and Therapy - Year 2016, Vol 2, Issue 2
Abstract
Malignant melanoma is a serious health problem once the current chemotherapy exhibits resistance to traditional drugs. Several challenges must be overcome during drug design in order to increase the efficacy and safety of the new drugs. Therefore, the specific chemical release of cytotoxic agents near to the target is an attractive approach to improve the anticancer activity and reduce the systemic toxicity. Herein, this review article describes the advances in the development of targeted prodrugs for the treatment of malignant melanoma.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP344155
- DOI 10.23937/2469-5750/1510019
- Views 114
- Downloads 0
New Insights and Therapeutic Implications in Cutaneous Melanoma
Melanoma is a highly aggressive tumour with poor prognosis in the metastatic stage that arises and evolves due to a myriad of genetic and epigenetic events. Among these, the interaction between epigenetic alterations (i....
Usage of Skin Tumor Images on the Internet for Personal Computer Based Automated Cognition
Visual diagnosis of skin tumors is one of the most important steps in dealing with them. Nowadays, artificial intelligence has been booming and technology of automated cognition by computer has been improved. One of the...
Targeting Myostatin Signaling in Skin Healing
Myostatin is a protein well described for its role in decelerating muscle anabolism. Most studies targeting the Myostatin pathway were performed in muscle wasting diseases. Recent studies unveil a potential approach to i...
Two-Year Evaluation of Either Bilobed Flap or Full Thickness Skin Graft as a Closure Technique of the Nasal Tip
Background: There is no clarity if a bilobed flap is the best treatment of choice for reconstruction of nasal tip defects. Method: The nose of twenty patients was photographed 2 years after surgical excision of skin can...
A Fatal Infection due to Gordonia Terrae
A 53-year-old man with a history of poliomyelitis underwent left total hip arthroplasty in December 2011. His past medical history was not significant except the medical conditions described disease. The patient had deve...